Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy

CD27 is a costimulatory molecule that provides a complementary target to the PD-1/PD-L1 checkpoint axis on T cells. Combining a CD27 agonist antibody with PD-1/PD-L1 blockade has shown synergistic antitumor activity in preclinical models, which led to clinical studies of the combination in cancer pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Immunother
Main Authors: Vitale, Laura A., He, Li-Zhen, Thomas, Lawrence J., Wasiuk, Anna, O’Neill, Thomas, Widger, Jenifer, Crocker, Andrea, Mills-Chen, Laura, Forsberg, Eric, Weidlick, Jeffrey, Patterson, Colleen, Hammond, Russell A., Boyer, James, Sisson, Crystal, Alvarado, Diego, Goldstein, Joel, Marsh, Henry C., Keler, Tibor
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7511290/
https://ncbi.nlm.nih.gov/pubmed/32451681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02610-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados